

Convocatorias clúster Salud (WP 20252)

Horizonte Europa

**Jornada Informativa: "Convocatorias WP2025 Clúster Salud de
HORIZONTE EUROPA y WP2025 Misión Cáncer"**

Marta Marín marta.marin@fecyt.es
Madrid, 13 de junio de 2025



GOBIERNO
DE ESPAÑA

MINISTERIO
DE CIENCIA, INNOVACIÓN
Y UNIVERSIDADES



oficina
europea



Clúster Salud

Health
Cluster
8.246M€



Programa de Trabajo




Misión Cáncer ($\leq 10\%$ Pilar II)



Partenariados ($< 50\%$ Pilar II)




Por dónde empezar...



The screenshot shows the homepage of the EU Funding & Tenders Portal. At the top, there is a header with the European Commission logo and the text "EU Funding & Tenders Portal". To the right of the header are "Sign in" and "EN" buttons. Below the header is a navigation bar with several menu items: "Home", "Funding", "Procurement", "Projects & Results", "News & Events", "Work as an expert", and "Guidance & Documents". A search bar is located on the right side of the navigation bar. Below the navigation bar is a large banner image featuring a collage of various project photos and several yellow stars. Below the banner, the text "Discover the funding & tenders opportunities" is displayed, followed by a link to "Find out how to participate by following these key steps." Below this, there are four boxes, each containing a title and a description of a key step:

- Find calls for proposals**
Explore the available EU funding opportunities by searching for calls for proposals within your topics of interest, find partners and submit a proposal.
- Find calls for tenders**
Find business opportunities in the calls for tenders managed by EU institutions, bodies and agencies.
- View projects and results**
Browse through EU funded projects and learn about the results. Invest in opportunities and get inspired by the highlights and success stories.
- Work as an expert**
Proposals and projects need evaluations, monitoring and domain-specific knowledge advice from experts.

Por dónde empezar... F&T Portal



Discover the funding & tenders opportunities



Find out how to participate by following these key steps.

Find calls for proposals

Explore the available EU funding opportunities by searching proposals within your topics of interest, find partners and submit a proposal.

View projects and results

Browse through EU funded projects and learn about the results in opportunities and get inspired by the highlights and success stories.



Por dónde empezar... F&T Portal



European Commission

EU Funding & Tenders Portal

Sign in

EN

Home

Funding

Procurement

Projects & tenders

News & events

Work as an expert

Guidance & documents

Search

Guardar



Filters

Quick search

HORIZON-HLTH-2025

Programming period

Horizon Europe (HORIZON)

Call

Submission status

All filters

GRANTS RECOMMENDED FOR YOU

Do you want to receive personalised recommendations? [Log in](#) to your F&T profile or [register](#) an account to activate them.

20 item(s) found

Programme Horizon Europe (HORIZON)

Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GRI-CIP)

HORIZON-HLTH-2025-01-DISEASE-05

Call for proposal

Opening date: 22 May 2025

Deadline date: 16 September 2025

Single-stage

Open For Submission

Programme: Horizon Europe (HORIZON)

Type of action: HORIZON Coordination and Support Actions

Leveraging multimodal data to advance Generative Artificial Intelligence applications (LEVERAGING)

HORIZON-HLTH-2025-01-TOOL-03

Call for proposal

Opening date: 22 May 2025

Deadline date: 16 September 2025

Single-stage

Open For Submission

Programme: Horizon Europe (HORIZON)

Type of action: HORIZON Research and Innovation Actions

Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant infections (TESTING)

HORIZON-HLTH-2025-01-DISEASE-01

Call for proposal

Opening date: 22 May 2025

Deadline date: 16 September 2025

Single-stage

Open For Submission

Programme: Horizon Europe (HORIZON)

Type of action: HORIZON Research and Innovation Actions

Partner search announcements

21 Searches of partners to collaborate on this topic

View / Edit

LEARs, Account Administrators or self-registrants can publish partner requests for open and forthcoming topics after logging into this Portal, as well as any user having an active public Person profile.

Start submission

Need help?

To access the Electronic Submission Service, please click on the submission-button next to the **type of action** and the **type of model grant agreement** that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.

To access existing draft proposals for this topic, please login to the Funding & Tenders Portal and select the My Proposals page of the My Area section.

Please select the type of your submission:

☐ HORIZON Coordination and Support Actions [HORIZON-CSA], HORIZON Lump Sum Grant [HORIZON-AG-LS]

Start submission

Topic Q&As

5 item(s) found

General FAQ

Filter...

In the context of topic HORIZON-HLTH-2025-01-TOOL-05, is there any restriction related to the budget distribution of my proposal?

As indicated in the specific topic conditions, the proposed EU contribution going to small and medium-sized enterprises (SMEs) must be 50% or more of the total EU contribution to the...

In the context of topic HORIZON-HLTH-2025-01-TOOL-05, how many beneficiaries can I include in my proposal? Is there a limit?

As indicated in the specific topic conditions, in addition to the eligibility conditions as described in General Annex B, the consortium must be composed of at most 5 legal entities ...

In the context of topic HORIZON-HLTH-2025-01-TOOL-05, can I subcontract part of the action?

Subcontracting costs for the action are eligible. For more information, please refer to the relevant sections of the General Model Grant Agreement.

In the context of topic HORIZON-HLTH-2025-01-TOOL-05, what kind of regulatory approval is needed?

In order for your proposal to be eligible for this topic, you must provide evidence of regulatory approval for a phase I clinical study in at least one EU country, issued by the nati...

Is this topic a Lump Sum (LS) topic?

No, this topic is not using the Lump Sum funding model.



GOBIERNO DE ESPAÑA

MINISTERIO DE CIENCIA E INNOVACIÓN

FECYT

INNOVACIÓN

Programa de Trabajo Salud 2025

Mantenerse sano en una sociedad que cambia rápidamente

Vivir y trabajar en un ambiente que promueva la salud

Hacer frente a las enfermedades y reducir la carga de la enfermedad

Garantizar el acceso a una atención sanitaria innovadora, sostenible y de alta calidad

Desplegando todo el potencial de las nuevas herramientas, tecnologías y soluciones digitales para una sociedad sana

Mantener una industria de la salud innovadora, sostenible y competitiva a nivel mundial

**17 topics
competitivos**

**81 Proyectos
financiados**

**696 M€
contribución
CE**

- **2 partenariados – Brain Health, ERA4Health**
- **18 topics competitivos**
- **Evaluación en una (13) y dos fases (5)**
 - **Blind evaluation (Fase I)**
- **Modelo de costes LS y Costes reales**
- **Fecha apertura**
 - **13 de mayo 2025 (partnerships)**
 - **22 de mayo 2025**
- **Fecha de cierre**
 - **3 de junio 2025 (partnerships)**
 - **16 de septiembre 2025**
 - **16 de abril 2026 (Fase II)**

Qué se espera financiar

- ✓ Busca dar **solución** a necesidades europeas mediante un **enfoque interdisciplinar**
- ✓ Investigación básica y traslacional, **investigación clínica**, investigación de implementación, epidemiológica, ética, regulatoria, ambiental y socioeconómica + innovación.
- ✓ Proyectos **competitivos, innovadores y ambicioso** (basados en excelencia, impacto e implementación)
- ✓ Foco en el **impacto** de los proyectos y **contribución a políticas europeas**.
- ✓ **Pacientes y ciudadanos** en el centro y involucración de **usuarios finales**
- ✓ Los **topics son poco prescriptivos** y con pocos ejemplos. **Si no está excluido está incluido.**
- ✓ Están **abiertos a cualquier enfermedad** (excepto cuando se indica)



Programa de Trabajo 2025

Destination 1: STAYHLTH

Mantenerse sano en una sociedad que cambia rápidamente

IMPACTO: Personas de todas las edades de la UE se mantengan sanas, resistentes e independientes a pesar de los rápidos cambios de la sociedad gracias a estilos de vida y comportamientos más saludables.

- Improving the quality of life of persons with intellectual disabilities and their families

Programa de Trabajo 2025

Destination 2: ENVHLTH

Vivir y trabajar en un ambiente que promueva la salud

IMPACTO: que los entornos de vida y trabajo de las personas sean saludables y sostenibles gracias a una mejor comprensión de los determinantes medioambientales, laborales, sociales, económicos y relacionados con el sexo y el género.

- The impact of pollution on the development and progression of brain diseases and disorders
- Advancing knowledge on the impacts of micro- and nanoplastics on human health

Programa de Trabajo 2025

Destination 3: DISEASE

Hacer frente a las enfermedades y reducir la carga de la enfermedad

IMPACTO: mejorar la comprensión, prevención, diagnóstico, tratamiento, gestión y curación de las enfermedades para que los profesionales sanitarios mejoren su capacidad de abordar y gestionar las enfermedades reduciendo así la carga de morbilidad de los pacientes y permitiendo que los sistemas sanitarios funcionen con mayor eficacia

- Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections
- Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders
- Development of antibodies and antibody derived proteins for the prevention and treatment of infectious diseases with epidemic potential
- Leveraging artificial intelligence for pandemic preparedness and response
- *Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness*
- Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)
- Tackling high-burden for patients and underresearched medical conditions
- *European Partnership for Brain Health, European partnership fostering a European Research Area (ERA) for health research (Phase 2)*



Programa de Trabajo 2025

Destination 4: CARE

Garantizar el acceso a una atención sanitaria innovadora, sostenible y de alta calidad

IMPACTO: los sistemas sanitarios proporcionen un acceso equitativo a una asistencia sanitaria innovadora, sostenible y de alta calidad gracias al desarrollo y la adopción de soluciones seguras, rentables y centradas en las personas .

- End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)

Programa de Trabajo 2025

Destination 5: TOOL

Desplegando todo el potencial de las nuevas herramientas, tecnologías y soluciones digitales para una sociedad sana

IMPACTO: que las tecnologías sanitarias, los datos, las nuevas herramientas y las soluciones digitales se apliquen eficazmente gracias a su suministro, integración y despliegue inclusivos, éticos, seguros y sostenibles en las políticas sanitarias y en los sistemas sanitarios y asistenciales

- Enhancing cell therapies with genomic techniques
- Advancing cell secretome-based therapies
- Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)
- Boosting the translation of biotech research into innovative health therapies

Programa de Trabajo 2025

Destination 6: IND

Mantener una industria de la salud innovadora, sostenible y competitiva a nivel mundial

IMPACTO: que la industria sanitaria de la UE sea innovadora, sostenible y competitiva a nivel mundial gracias a la mejora de la adopción de tecnologías de vanguardia e innovaciones (incluidas las innovaciones sociales) siendo menos dependientes de las importaciones de tecnologías sanitarias críticas.

- Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)
- Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices
- Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative (“breakthrough”) devices

Programa de Trabajo Salud 2025

TOPIC	€ total	€/ prop.	# prop.	RIA/IA/CSA	1/2-stage	Blind eval	LS/AC	SSH	Cluster	JRC	RESTRICTIONS	Other
HORIZON-HLTH-2025-03-STAYHLTH-01-two-stage: Improving the quality of life of persons with intellectual disabilities and their families	40M€	6-8M€	5	RIA	2-stage	YES	LS	YES	YES			
HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage: The impact of pollution on the development and progression of brain diseases and disorders	40M€	6-7M€	6	RIA	2-stage	YES	LS	YES	YES (2%)	JRC, EU AGENCY		
HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health	40M€	7-8M€	5	RIA	2-stage	YES	LS	YES	YES (2%)	JRC, EU AGENCY		
HORIZON-HLTH-2025-01-DISEASE-01: Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections	40M€	15M€	3	RIA	1-stage	NO	LS	YES			EU CONNEC	
HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders	50M€	6-8M€	7	RIA	2-stage	YES	LS	YES	YES		EU CONNEC	
HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential	50M€	10M€	5	RIA	1-stage	NO	LS					
HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response	35M€	6-8M€	5	RIA	1-stage	NO	AC	YES	YES		EU CONNEC	
HORIZON-HLTH-2025-01-DISEASE-06: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)	20M€	3-4M€	5	RIA	1-stage	NO	AC	YES	YES (GACD)			
HORIZON-HLTH-2025-01-DISEASE-07: Tackling high-burden for patients and under-researched medical conditions	30M€	6M€	5	RIA	1-stage	NO	AC	YES				Portfolio approach
HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)	40M€	15-20M€	2	RIA	1-stage	NO	AC	YES	YES	JRC	EU CONNEC	
HORIZON-HLTH-2025-01-TOOL-01: Enhancing cell therapies with genomic techniques	50M€	8-10M€	5	RIA	1-stage	NO	AC			JRC		Portfolio approach
HORIZON-HLTH-2025-01-TOOL-02: Advancing cell secretome-based therapies	40M€	9-13M€	3	RIA	1-stage	NO	AC			JRC		
HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)	50M€	15-17M€	3	RIA	1-stage	NO	AC	YES	YES	JRC		
HORIZON-HLTH-2025-01-TOOL-05: Boosting the translation of biotech research into innovative health therapies	80M€	4-8M€	10	RIA	1-stage	NO	AC					Evidence of regulatory approval 50% contribution to SME Max 5 entities, 4 years STEP Seal
HORIZON-HLTH-2025-01-IND-01: Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)	40M€	6-8M€	5	IA	1-stage	NO	LS			JRC		Commitment of first deployment in the EU
HORIZON-HLTH-2025-01-IND-02: Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices	4M€	4M€	1	CSA	1-stage	NO	LS					Coordinator in EU
HORIZON-HLTH-2025-03-IND-03-two-stage: Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative ("breakthrough") devices	40M€	6-8M€	5	RIA	2-stage	YES	LS	YES		JRC	EU CONNEC	

Single-stage calls

✓ PARTE A:


- Participantes (incluido la tabla de investigadores y el GEP)
- Tabla presupuesto desglosado
- Autoevaluación de ética y seguridad

✓ PARTE B:

- RIA, IA: 45 páginas (+LS: 50 pág)
- CSA: 30 pág. (+LS: 33 pág.)
- Se evalúa Excelencia (4/5), Impacto (4/5), Implementación (4/5). Puntuación total 12/15

✓ Anexo LS (si aplica)

✓ Anexos de estudios clínicos, ética



Deadline: 16 de Septiembre 2025

2-stage calls

1ª fase

✓ PART A:

- Participantes (simplificado)
- Presupuesto general

TOTAL Requested EU contribution to eligible costs (Requested grant amount) - EUR	
--	--

✓ PART B:

- 10 páginas
- Se evalúa Excelencia (4/5) e Impacto (4/5)
- Evaluación ciega: *Organisation names, acronyms, logos or names of personnel should not appear in Part B*



Deadline: 16 de Septiembre 2025

Pasan a segunda fase **3.5-4x presupuesto**

2ª fase

✓ PARTE A:

- Participantes (incluido la tabla de investigadores y el GEP)
- Tabla presupuesto desglosado
- Autoevaluación de ética y seguridad
- Justificar modificaciones substanciales respecto a la primera fase

Two-stage calls

The full stage-2 proposal must be consistent with the short outline proposal submitted to the stage 1 – in particular with respect to the proposal characteristics addressing the concepts of excellence and impact.

Are there substantial differences compared to the stage-1 proposal?


☐ Yes ☐ No

✓ PARTE B:

- RIA, IA: 45 páginas (+LS: 50 pág)
- CSA: 30 pág. (+LS: 33 pág.)
- Se evalúa **Excelencia (4/5), Impacto (4/5), Implementación (4/5). Puntuación total 12/15**

✓ Anexo LS (si aplica)

✓ Anexos de estudios clínicos, ética



Deadline: 16 de abril 2026

Blind evaluation



Proposal submission

Part A - complete as usual

Part B – avoid disclosing organizational names, acronyms, logo nor name of personnel. Proposals with blacked out names and information are not preferred but accepted.

Guidance for blind evaluations
Proposals submitted to a call taking part in the blind evaluation pilot must be anonymous: proposals may not contain any direct or indirect reference to the organisations or persons participating in the proposals. This means that participants must not disclose applicants' organisation names, acronyms, logos nor names of personnel in the Part B of the application (the narrative uploaded as a pdf document). In addition, names of proposers or their organisations should not be potentially identifiable indirectly, via, for instance, links to web pages or through references to their role and previous experience. The proposal can include references to their own publications if there is no emphasis that the publication is authored by one or more of the proposers. The proposal will be declared inadmissible if its anonymity is not respected in the part B of the application. Information on the identity of participants should be included only in proposal Part A (the structured online web forms).
<u>How to insert references to publications</u> The proposal can include references to participants' own publications if there is no emphasis that the publication is authored by one or more of the proposers. For example, the following statement will not be admissible: <i>'For climate impact, we will use greenhouse gas emission intensities, following a methodology developed previously by a project partner (Dalin et al.)'</i> but the following would be ok: <i>'For climate impact, we will use greenhouse gas emission intensities, following the methodology described in Dalin et al.'</i>
<u>Examples of statements resulting in inadmissible proposals</u> - 'Most of project's participants have been involved in the previous H2020 project, NANOCOM...' - 'For climate impact, we will use greenhouse gas emission intensities, following a methodology developed previously by a project partner (Dalin et al.)' - 'This task in WP3 will be based on outputs generated by some participants of the consortium', (with a link in the footnote to a YouTube video or webpage where participants can be identified) - 'The consortium includes the largest research institute in France' - 'Partner 3 is the leading company in Spain for wind turbine installation' - 'Our current research expands our previous findings described in a recently published article (Wiliam et al, 2022)' - 'The consortium consists of leaders in the high tech industry, including the biggest in terms of capital constructor of micro chips ' - 'The coordinator organisation was the one who first introduced the concept of m-RNA in vaccines' - 'The consortium consists of 2 research centres (including an international one based in Geneva) and the oldest university in Belgium'

Blind evaluation



Guidance for evaluators

- ✓ Should Experts notice any direct or indirect identification of the applicant, they should notify the staff officer.
- ✓ Experts should evaluate the proposal blindly, without taking extra steps to investigate based on the information included in the proposal, who is behind the project.
- ✓ Listing R&I activities, including on-going or finished projects, does not necessarily entail that the applicants are also participants of those mentioned activities.
- ✓ The proposal can include references to participants' own publications if there is no emphasis that the publication is authored by one or more of the proposers.
- ✓ Names of past projects can be mentioned, but it cannot be explicitly indicated that the proposal is a continuation of these projects or that the partners from the past projects overlap with project partners of the current proposal.
- ✓ The name of the city and its characteristics can be mentioned, provided that there is no explicit indication in the proposal, that any of the applicants are from this location (even if this would be in reality the case). Otherwise, if the participant wants to mention that one of project partners is coming from/ is closely connected with the given city, then the city name should not be mentioned and the city should be only vaguely described by its characteristics, which would not allow for its identification

Blind evaluation



PUBLICACIONES	For climate impact, we will use greenhouse gas emission intensities, following a methodology developed previously <u>by a project partner</u> (Dalín et al.)	'For climate impact, we will use greenhouse gas emission intensities, following the methodology described in Dalín et al.'
PROJECT	'Most of project's <u>participants have been involved in the previous</u> H2020 project, NANOCOM...'	The project is based on results from a h2020 project, NANOCOM
COHORTS	The project will count with data from the <u>Spanish CoRIS cohort</u>	The project will count with data from a large VIH cohort.
PAISES	The consortium includes <u>the largest</u> research institute in France	The consortium includes a (large) research institute in France
EXPERTISE	'Partner 3 is <u>the leading company in Spain</u> for wind turbine installation'	'Partner 3 is a leading company in Spain for wind turbine installation' (if there are 10 companies) 'Partner 3 is a company for wind turbine installation'

Costes reales vs Lump Sum

COSTES REALES

1. Rellenar tabla de formularios online (Parte A)

Application Forms

Proposal ID XXXXXXXX Acronym XXXXXXXX

3 – Budget for the proposal

No	Participant name	Country	Estimated expenditure						Estimated income				Total estimated income (h) = (g) + (i) + (j)
			Estimated eligible costs						Requested EU contribution to eligible costs (f) = (d) * (e)	Revenues		Other sources of financing (j)	
			A. Personnel costs (a)	B. Subcontracting costs (b)	C. Purchased costs		D. Other cost categories (d)	E. Indirect costs (e) = (a) + (b) + (c) + (d) * 25%					
					C.1 Travel and subsistence (c1)	C.2 Equipment (c2)				C.3 Other goods, works and services (c3)			
1	Participant 1	NL											
2	Participant 2	LB											
	Affiliated Entity	LB											
3	Participant 3	DE											
	Associated Partner	AR											
Total													

LUMP SUM

1. Rellenar Excel presupuesto detallado
2. Rellenar tabla de formularios online (Parte A)

Lump sum breakdown

ESTIMATED BREAKDOWN OF THE LUMP SUM PER WORK PACKAGE AND PER BENEFICIARY						
	Work Package 1	Work Package 2	Work Package 3	Work Package 4	Totals	Pct
BENEFICIARIES						
Beneficiary 1	62.812,50	9.250,00	9.750,00	46.125,00	127.937,50	49,9%
Beneficiary 2	11.625,00	18.750,00	28.750,00	17.500,00	76.625,00	25,9%
Affiliated entity to BE2	16.312,50	0,00	7.000,00	11.625,00	34.937,50	11,8%
Beneficiary 3	10.762,50	14.568,75	19.206,25	11.881,25	56.218,75	19,0%
Totals:	101.512,50	42.568,75	64.706,25	86.931,25	295.718,75	100,0%
Pct:	34,3%	14,4%	21,9%	29,4%		

Part A (online forms)

No	Name of Beneficiary	Country	Requested grant amount
1			0,00
Total			0,00

3. Guardar como “.xlsx” o “.xls” para eliminar macros
4. Subir archivo como Anexo a la Parte B

Administrative forms (Part A)

Edit forms View history Print preview

Part B and Annexes

In this section you may upload the technical annex of the proposal (in PDF format only) and any other requested attachments.

Part B Upload

Annex – Detailed budget table Upload

← BACK TO PARTICIPANTS LIST VALIDATE SUBMIT

Costes reales vs Lump Sum

COSTES REALES

- Rellenar tabla 3.1g: 'Subcontracting costs' items

Participant Number/Short Name		
	Cost (€)	Description of tasks and justification
Subcontracting		

- Rellenar tabla 3.1h: 'Purchase costs' items

Participant Number/Short Name		
	Cost (€)	Justification
Travel and subsistence		
Equipment		
Other goods, works and services		
Remaining purchase costs (<15% of pers. costs)		
Total		

- Rellenar tabla 3.1j: 'In-kind contributions' provided by third parties (**solo free-of-charge)

Participant Number/Short Name			
Third party name	Category	Cost (€)	Justification
	Select between		
	Seconded personnel		
	Travel and subsistence		
	Equipment		
	Other goods, works and services		
	Internally invoiced		

LUMP SUM

- Rellenar tabla 3.1g: 'Subcontracting costs' items

Participant Number/Short Name		
	Cost (€)	Description of tasks and justification
Subcontracting		

- Rellenar tabla 3.1h: 'Purchase costs' items

Participant Number/Short Name		
	Cost (€)	Justification
Travel and subsistence		
Equipment		
Other goods, works and services		
Remaining purchase costs (<15% of pers. costs)		
Total		

- Rellenar tabla 3.1j: 'In-kind contributions' provided by third parties (**solo free-of-charge)

Participant Number/Short Name			
Third party name	Category	Cost (€)	Justification
	Select between		
	Seconded personnel		
	Travel and subsistence		
	Equipment		
	Other goods, works and services		
	Internally invoiced		

Portfolio approach

*In order to ensure a balanced project portfolio with regard to the medical condition/ therapeutic area targeted, grants will be awarded (within available budget) to proposals not only in order of ranking but also in function of the **highest ranked proposals in different medical conditions/ therapeutic areas**, provided that the applications attain all thresholds available.*

Portfolio (DISEASE-07):

- Myalgic encephalomyelitis/chronic fatigue syndrome,
- Autism,
- Gynaecological diseases,
- Low back pain,
- Other,

Portfolio (TOOL-01):

- Cancer and oncology
- Nervous and sensory system
- Cardiovascular and circulatory system
- Endocrinology and metabolic system
- Musculoskeletal system
- Digestive system
- Infectious diseases
- Respiratory system
- Dermatology
- Immune system and auto-immune diseases
- Other

Criterios de desempate y priorización

For each group of proposals with the same score, starting with the group achieving the highest score and continuing in descending order:

- 1) Proposals that address aspects of the call that have not otherwise been covered by more highly ranked proposals will be considered to have the highest priority.
- 2) The proposals identified under 1), if any, will themselves be prioritised according to the scores they have been awarded for 'Excellence'. When these scores are equal, priority will be based on scores for 'Impact'. In the case of 'Innovation actions', priority will be given to the score for 'Impact', followed by that for 'Excellence'.
- 3) If necessary, the gender balance among the researchers with a leading role named in the researchers table in the proposal, will be used as a factor for prioritisation.
- 4) If necessary, any further prioritisation will be based on geographical diversity, defined as the number of Member States or Associated Countries represented in the proposal, not otherwise receiving funds from projects higher up the ranking list (and if equal in number, then by budget).

GA WP 2023-2024

- 3) If necessary, the gender balance among the researchers named in the researchers table in the proposal, will be used as a factor for prioritisation.

Researchers involved in the proposal									
Include only the researchers involved in the proposal, (see below definition of 'researcher'). You do not need to include in the table the identity of other persons involved in the proposal who are not researchers.									
'Researchers are professionals engaged in the conception or creation of new knowledge. They conduct research and improve or develop concepts, theories, models, techniques instrumentation, software or operational methods. (Frascati Manual 2015)'									
Include also person in charge of the proposal if a researcher.									
Title	First Name	Last Name	Gender	Nationality	E-mail	Career stage ¹	Role of researcher (in the project)	Reference Identifier	Type of identifier
			[Woman] [Man] [Non-binary]			[Category A – Top grade researcher] [Category B – Senior researcher] [Category C – Recognised researcher] [Category D – First stage researcher]	[Leading] [Team member]		[ORCID] [Researcher Id] [Other - specify]

Participación en CL1

¿Quién puede participar?

Proyectos colaborativos → Composición del consorcio

- **Regla 3-3:** mínimo 3 entidades legales independientes de 3EEMM o Países Asociados (al menos 1 EEMM)

Cualquier entidad legal*,
independientemente el lugar del mundo en
donde esté emplazada, puede formar parte de
un consorcio solicitante

	RESTRICCIÓN	ENLACES
Restricciones para proteger <u>redes de comunicación EU y otras infraestructuras críticas</u> EU toolbox on 5G cybersecurity of 2023 → identificar “<u>proveedores de alto riesgo</u>” (ZTE y Huawei)	En convocatorias/proyectos que incorporan elementos relacionados con desarrollo de redes de comunicación EU (5G, post-5G, etc.) no pueden participar “proveedores de alto riesgo” NO PARTICIPACIÓN ni como beneficiarios, ni AE, ni AP (excepciones justificadas - caso a caso)	Segundo informe sobre los avances de los Estados miembros en la aplicación del conjunto de herramientas de la UE sobre ciberseguridad 5G, junio 2023 COMUNICACIÓN DE LA COMISIÓN: Aplicación del conjunto de instrumentos de la UE para la seguridad de las redes 5G 15.6.2023 C(2023) 4049 final

Participación en CL1

¿Quién puede recibir financiación?

- Estados Miembros (EEMM)
- Países Asociados: ej. Islandia, Israel, Noruega, UK, Canadá, Suiza*
- Terceros países con ingresos bajo-medio
- Otros países previstos en la Convocatoria ej EEUU
- Otros países con participación esencial (se evalúa caso a caso)
- Hay países que tienen previsto **Complementary funding mechanisms in third countries** para la participación en HE


* Transitional Arrangement

AI factories

El objetivo es apoyar las aplicaciones de la IA para la ciencia, centrándose en la inteligencia artificial ética, el aprendizaje automático, y modelos fundacionales de vanguardia e **IA generativa**.



Las instituciones pueden solicitar la cuota de tiempo de acceso de la Unión a los superordenadores – **priorizarán proyectos financiados por HE-CL1**



Key Sectors	AT	BG	DE	EL	ES	FI	FR	IT	LU	PL	SE	SI
Health & Life Sciences	●		●	●	●	●	●	●		●	●	●

Novedades en el template

Descargar el template de la [convocatoria](#)

- Simplificación de la sección de Open Science + Research Data Management
- Eliminación de la sección de metodología/IA confiable
- Eliminación de la referencia al principio “Do Not Significant Harm”
- Debemos declarar si hemos usado IA en la generación de algún apartado de la propuesta
- Versión del Anexo de EECC (V4.3 –07.04.2025)

Guidance on the use of generative AI tools for the preparation of the proposal
When considering the use of generative artificial intelligence (AI) tools for the preparation of the proposal, it is imperative to exercise caution and careful consideration. The AI-generated content should be thoroughly reviewed and validated by the applicants to ensure its appropriateness and accuracy, as well as its compliance with intellectual property regulations. Applicants are fully responsible for the content of the proposal (even those parts produced by the AI tool) and must be transparent in disclosing which AI tools were used and how they were utilized. Specifically, applicants are required to: • Verify the accuracy, validity, and appropriateness of the content and any citations generated by the AI tool and correct any errors or inconsistencies. • Provide a list of sources used to generate content and citations, including those generated by the AI tool. Double-check citations to ensure they are accurate and properly referenced. • Be conscious of the potential for plagiarism where the AI tool may have reproduced substantial text from other sources. Check the original sources to be sure you are not plagiarizing someone else's work. • Acknowledge the limitations of the AI tool in the proposal preparation, including the potential for bias, errors, and gaps in knowledge.



Tips para preparar la propuesta

EXCELENCIA

OBJETIVOS SMART

Claros y relevantes para el *scope* indicado
Cuantificables y verificables
Realistas

PROYECTO PROPUESTO

Ambicioso y que vaya más allá en el estado del arte
I+D innovadora
Madurez en línea con el topic y tipo de acción

METODOLOGÍA

Conceptos y modelos claros y ambiciosos
Relación con otros proyectos o iniciativas
Clara interdisciplinariedad

OTROS

Dimensión de género en la investigación
Open Science
Integración de ciencias sociales y humanidades (SSH)



Tips para preparar la propuesta

IMPACTO

CREDIBILIDAD DE LAS VÍAS DE IMPACTO

Cómo contribuye el proyecto a los resultados esperados (*expected outcomes*) e impactos (*expected impacts*)

Identificar poblaciones diana

Escala y alcance del impacto cuantificado

Barreras y medidas de mitigación

MEDIDAS PARA MAXIMIZAR EL IMPACTO

Plan de diseminación

Plan de comunicación, incluir acciones para las poblaciones diana

Explotación y protección de la IP

RESUMEN




Tips para preparar la propuesta

IMPACTO

RESUMEN

KEY ELEMENT OF THE IMPACT SECTION



Tips para preparar la propuesta

CALIDAD DE LA IMPLEMENTACIÓN

CALIDAD Y EFECTIVIDAD DE LOS PAQUETES DE TRABAJO

Estructura lógica de los PT y **temporización adecuada**

Recursos en línea con los objetivos y deliverables

Riesgos críticos y medidas de mitigación

CAPACIDAD Y COMPETENCIAS DE LOS SOCIOS

Encaje de los conocimientos, la experiencia, las habilidades de los socios para desarrollar el proyecto

Complementariedad y necesidad de los socios


Competencias de SSH, género, open science

Acceso a infraestructuras necesarias

Involucración comercial o industrial (si es relevante)



Más información:



HNN 3.0 - Supporting Tools

Please note that some tools / documents are for Health NCPs only. If you are Health NCP, we invite you to login or create an account to access Health NCP specific tools.

Question & Answer (Q&A) Documents

- InfoDay Cluster 1 "Health" - Q&A on Calls 2023
- InfoDay Cluster 1 "Health" - Q&A on Calls 2024
- IHI Call 8 - Call Days Q&A
- IHI Call 9&10 - Call Days Q&A
- Workshop on Pre- Commercial Procurement in Horizon Europe
- Blind Evaluations in Horizon Europe - Q&A

Communication and Dissemination of project results in Health (HE and H2020)

HaDEA Webinar "How to communicate about and disseminate project results under Horizon Europe Cluster 1 'Health' and Horizon 2020"

Watch recording and Download presentation


Events

- May 2025
- May 5, 2025
- HNN3.0 | Brokerage event on Horizon Europe Cluster 1 2025 calls
- May 6, 2025



Horizon Europe National Contact Points Portal

Where the NCP knowledge meets your needs



Salud

Buscar todas las palabras

Horizonte Europa – Clúster 1 - Salud: Infoday Nacional 2025

14 de Mayo de 2025

El 14 de mayo CDTI organiza en colaboración con FECYT y HADEA, una jornada informativa sobre las convocatorias 2025 del Clúster 1 de Salud de Horizonte Europa. Durante la misma, con la...

Horizon Europe info days – EU Missions

22 de Mayo de 2025 - 23 de Mayo de 2025

Los días 22 y 23 de mayo, la Comisión Europea organiza el evento "Horizon Europe- EU Missions". Será un evento en formato virtual, que tiene como objetivo...

Infoday Europeo Cluster 1

22 de Mayo de 2025

Infoday organizado por la Comisión Europea donde se presentarán los tópicos 2025 del Clúster de Salud y habrá sesiones para Q&A.



Marta de Diego

CDTI
marta.dediego@cdti.es
+34 91 581 55 62



Marta Marín

FECYT
marta.marin@fecyt.es
+34 91 425 09 09

Más información:



[Disponible grabación y presentaciones](#)



[Disponible grabación y presentaciones](#)



[Disponible presentación de topics y Q&A](#)

	Marta de Diego CDTI marta.dediego@cdti.es +34 91 581 55 62		Marta Marín FECYT marta.marin@fecyt.es +34 91 425 09 09
---	--	---	---



GOBIERNO
DE ESPAÑA

MINISTERIO
DE CIENCIA
E INNOVACIÓN



oficina
europea

